Novartis Vaccines Launches Fluvirin Vaccine in US Market
From EquityBites (July 30, 2010)
Healthcare solutions supplier Novartis Vaccines (NYSE:NVS) stated
on Thursday that the company has commenced the shipment of
approximately 40m doses of Fluvirin vaccine to the US to support
the seasonal influenza vaccination for the 2010-2011 flu
season.
This initiation allows health care professionals in the US to protect their patients well in advance of this year's flu season.
The Fluvirin influenza virus vaccine has been approved by the US Food and Drug Administration (FDA) and recommended for patients four years of age and older, claimed the company.
Fluvirin will be available to health care professionals in both pre-filled syringes and multi-dose vials, added the company.
((Comments on this story may be sent to tww.feedback@m2.com))
Posted: July 2010
